Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
已完结
10
由 士多啤梨 发布于 2025/10/29 14:59:29
DOI:10.1038/s41375-024-02506-1
作者：Philippe Moreau,?Thierry Facon,?Saad Z. Usmani,?Nizar Bahlis,?Noopur Raje,?Torben Plesner,?Robert Z. Orlowski,?Supratik Basu,?Hareth Nahi,?Cyrille Hulin,?Hang Quach,?Hartmut Goldschmidt,?Michael O’Dw
文献类型：期刊论文
补充材料：只需要正文
作者：Philippe Moreau,?Thierry Facon,?Saad Z. Usmani,?Nizar Bahlis,?Noopur Raje,?Torben Plesner,?Robert Z. Orlowski,?Supratik Basu,?Hareth Nahi,?Cyrille Hulin,?Hang Quach,?Hartmut Goldschmidt,?Michael O’Dw
文献类型：期刊论文
补充材料：只需要正文
Springer
上一个求助:
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:
ElsevierBortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:ElsevierBortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
京公网安备 11010802042870号
